Robert Bruce's SUPN Position Overview
Robert Bruce (via Bruce & Co., Inc.) currently holds 100,000 shares of Supernus Pharmaceuticals, Inc. (SUPN) worth $5.17 M, representing 1.48% of the portfolio. First purchased in 2014-Q2, this long-term strategic position has been held for 48 quarters.
Based on 13F filings since 2013, Robert Bruce has maintained a long-term strategic position in SUPN, representing a significant commitment to this investment thesis. Largest addition occurred in Q3 2014, adding 300,000 shares. Largest reduction occurred in Q3 2015, reducing 300,000 shares.
Analysis based on 13F filings available since 2013 Q2
Robert Bruce's Supernus Pharmaceuticals (SUPN) Holding Value Over Time
Track share changes against reported price movement
Quarterly Supernus Pharmaceuticals (SUPN) Trades by Robert Bruce
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +17,895 | Add 21.80% | 100,000 | $51.69 |
| Q1 2023 | -10,000 | Reduce 10.86% | 82,105 | $36.23 |
| Q4 2022 | -30,000 | Reduce 24.57% | 92,105 | $35.67 |
| Q3 2022 | -80,000 | Reduce 39.58% | 122,105 | $33.85 |
| Q2 2022 | -20,000 | Reduce 9.00% | 202,105 | $28.92 |
| Q1 2022 | -180,000 | Reduce 44.76% | 222,105 | $32.32 |
| Q4 2020 | +50,000 | Add 14.20% | 402,105 | $25.16 |
| Q4 2019 | +204,047 | Add 137.82% | 352,105 | $23.72 |
| Q3 2018 | -10,000 | Reduce 6.33% | 148,058 | $50.35 |
| Q2 2018 | -20,000 | Reduce 11.23% | 158,058 | $59.85 |
| Q3 2017 | +143,477 | Add 414.90% | 178,058 | $40.00 |
| Q2 2017 | -30,000 | Reduce 46.45% | 34,581 | $43.09 |
| Q1 2017 | -100,000 | Reduce 60.76% | 64,581 | $31.29 |
| Q3 2016 | -60,000 | Reduce 26.72% | 164,581 | $23.00 |
| Q1 2016 | -30,000 | Reduce 11.78% | 224,581 | $15.25 |
| Q4 2015 | -140,000 | Reduce 35.48% | 254,581 | $13.44 |
| Q3 2015 | -300,000 | Reduce 43.19% | 394,581 | $14.03 |
| Q4 2014 | +294,581 | Add 73.65% | 694,581 | $8.30 |
| Q3 2014 | +300,000 | Add 300.00% | 400,000 | $8.69 |
| Q2 2014 | +100,000 | New Buy | 100,000 | $10.95 |
Robert Bruce's Supernus Pharmaceuticals Investment FAQs
Robert Bruce first purchased Supernus Pharmaceuticals, Inc. (SUPN) in Q2 2014, acquiring 100,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Robert Bruce has held Supernus Pharmaceuticals, Inc. (SUPN) for 48 quarters since Q2 2014.
Robert Bruce's largest addition to Supernus Pharmaceuticals, Inc. (SUPN) was in Q3 2014, adding 400,000 shares worth $3.48 M.
According to the latest 13F filing for Q1 2026, Robert Bruce's firm, Bruce & Co., Inc., owns 100,000 shares of Supernus Pharmaceuticals, Inc. (SUPN), valued at approximately $5.17 M.
As of the Q1 2026 filing, Supernus Pharmaceuticals, Inc. (SUPN) represents approximately 1.48% of Robert Bruce's publicly disclosed stock portfolio, making it one of their key holdings.
Robert Bruce's peak holding in Supernus Pharmaceuticals, Inc. (SUPN) was 694,581 shares, as reported at the end of Q4 2014.